Leon Hooftman

2.6k total citations · 1 hit paper
35 papers, 1.2k citations indexed

About

Leon Hooftman is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Leon Hooftman has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Molecular Biology and 11 papers in Hematology. Recurrent topics in Leon Hooftman's work include Peptidase Inhibition and Analysis (11 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Leon Hooftman is often cited by papers focused on Peptidase Inhibition and Analysis (11 papers), Multiple Myeloma Research and Treatments (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Leon Hooftman collaborates with scholars based in United Kingdom, United States and Netherlands. Leon Hooftman's co-authors include Timothy H. Mathew, Stephen J. Tomlanovich, C F Barker, Carl G. Groth, Philip F. Halloran, Ashok Rakhit, Karen Rittweger, E Taskinen, Timo Paavonen and Eleanor L. Ramos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Leon Hooftman

33 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS

1997 469 citations Philip F. Halloran, Timothy H. Mathew et al. Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leon Hooftman United Kingdom	14	548	319	302	229	197	35	1.2k
R. Shorthouse United States	18	400 0.7×	426 1.3×	275 0.9×	121 0.5×	56 0.3×	35	969
Milagros Lagman United States	11	370 0.7×	440 1.4×	502 1.7×	605 2.6×	35 0.2×	19	1.6k
T. Mohanakumar United States	21	473 0.9×	692 2.2×	191 0.6×	139 0.6×	16 0.1×	74	1.4k
Attaphol Pawarode United States	17	180 0.3×	297 0.9×	135 0.4×	244 1.1×	17 0.1×	64	1.1k
María José Herrero Spain	19	197 0.4×	146 0.5×	442 1.5×	310 1.4×	17 0.1×	90	1.2k
F L Delmonico United States	12	201 0.4×	277 0.9×	161 0.5×	116 0.5×	15 0.1×	22	951
Kenneth E. Drazan United States	23	81 0.1×	615 1.9×	593 2.0×	295 1.3×	24 0.1×	30	1.5k
Witold B. Rybka United States	21	225 0.4×	320 1.0×	254 0.8×	676 3.0×	9 0.0×	79	1.7k
Marco R. de Groot Netherlands	14	45 0.1×	189 0.6×	230 0.8×	678 3.0×	25 0.1×	28	1.1k
Hildegard Greinix Austria	14	54 0.1×	164 0.5×	265 0.9×	427 1.9×	14 0.1×	41	1.1k

Countries citing papers authored by Leon Hooftman

Since Specialization

Citations

This map shows the geographic impact of Leon Hooftman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leon Hooftman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leon Hooftman more than expected).

Fields of papers citing papers by Leon Hooftman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leon Hooftman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leon Hooftman. The network helps show where Leon Hooftman may publish in the future.

Co-authorship network of co-authors of Leon Hooftman

This figure shows the co-authorship network connecting the top 25 collaborators of Leon Hooftman. A scholar is included among the top collaborators of Leon Hooftman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leon Hooftman. Leon Hooftman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chuang, Wan‐Long, Anchalee Avihingsanon, Chi-Yi Chen, et al.. (2025). LBP-004 Primary analysis of a phase 2b open-label study demonstrates VTP-300 administered with low-dose nivolumab is associated with meaningful reductions of HBsAg in chronic hepatitis B participants with HBsAg less than 200 IU/mL. Journal of Hepatology. 82. S71–S71.

Harrington, Kevin J., Erminia Massarelli, Sonja Visscher, et al.. (2024). Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).. Journal of Clinical Oncology. 42(16_suppl). 6003–6003. 9 indexed citations

Kong, Anthony, Begoña Aguilera, Sonja Visscher, et al.. (2024). 878P Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy. Annals of Oncology. 35. S627–S628.

Kong, Anthony, Begoña Aguilera, Douglas R. Adkins, et al.. (2023). Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.. Journal of Clinical Oncology. 41(16_suppl). 6028–6028. 4 indexed citations

Bruijnzeel, P. L. B., Achim Wach, Leon Hooftman, et al.. (2019). Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. Journal of Cystic Fibrosis. 19(2). 299–304. 40 indexed citations

Karpova, Darja, Susanne Bräuninger, Eliza Wiercinska, et al.. (2017). Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial. Journal of Translational Medicine. 15(1). 2–2. 36 indexed citations

Hooftman, Leon, Achim Wach, Johann Zimmermann, et al.. (2017). WS01.4 A randomised, double-blind, placebo-controlled, parallel-group, dose-escalation study of inhaled single doses of POL6014, a potent and selective reversible inhibitor of human neutrophil elastase (NE), in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis. 16. S2–S2. 1 indexed citations

Ossenkoppele, Gert J., Bob Löwenberg, Pierre Zachée, et al.. (2013). A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies. British Journal of Haematology. 162(2). 191–201. 34 indexed citations

Banerji, Udai, Leni van Doorn, Dionysis Papadatos-Pastos, et al.. (2012). A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research. 18(9). 2687–2694. 64 indexed citations

10.

Herpen, Carla M.L. van, Ferry A.L.M. Eskens, Maja J.A. de Jonge, et al.. (2010). A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. British Journal of Cancer. 103(9). 1362–1368. 22 indexed citations

11.

Moore, Hannah E., Emma L. Davenport, Emma Smith, et al.. (2009). Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Molecular Cancer Therapeutics. 8(4). 762–770. 44 indexed citations

12.

Reid, Alison, Andrew Protheroe, Gerhardt Attard, et al.. (2009). A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(15). 4978–4985. 29 indexed citations

13.

Talpaz, Moshe, Ashok Rakhit, Karen Rittweger, et al.. (2005). Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-α-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia. Clinical Cancer Research. 11(17). 6247–6255. 26 indexed citations

14.

Häyry, P, Timo Paavonen, E Taskinen, et al.. (2004). Protocol core needle biopsy and histological chronic allograft damage index as surrogate endpoint for Long-Term graft survival. Transplantation Proceedings. 36(1). 89–91. 5 indexed citations

15.

Yılmaz, Serdar, Timothy H. Mathew, E Taskinen, et al.. (2003). Protocol Core Needle Biopsy and Histologic Chronic Allograft Damage Index (CADI) as Surrogate End Point for Long-Term Graft Survival in Multicenter Studies. Journal of the American Society of Nephrology. 14(3). 773–779. 111 indexed citations

16.

Motzer, Robert J., Ashok Rakhit, John F. Thompson, et al.. (2002). Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma. Annals of Oncology. 13(11). 1799–1805. 38 indexed citations

17.

Motzer, Robert J., Ashok Rakhit, Michelle S. Ginsberg, et al.. (2001). Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology. 19(5). 1312–1319. 73 indexed citations

18.

Halloran, Philip F., Timothy H. Mathew, Stephen J. Tomlanovich, et al.. (1997). MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS. Transplantation. 63(1). 39–47. 469 indexed citations breakdown →

19.

Grinyó, J.M., Salvador Gil‐Vernet, Josep M. Cruzado, et al.. (1997). STEROID WITHDRAWAL IN MYCOPHENOLATE MOFETIL-TREATED RENAL ALLOGRAFT RECIPIENTS. Transplantation. 63(11). 1688–1690. 67 indexed citations

20.

Bullingham, Roy, et al.. (1994). Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers.. PubMed. 32(8). 409–14. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact